Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | Blank 4 | Frequency | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | chemotherapy immunotherapy radiotherapy or any ancillary therapy considered | 13 | 17 | food and drug administration | 16 | 11 | ||
| 2 | 1 | chemotherapy immunotherapy radiotherapy any ancillary therapy considered | 3 | therapy | 1 | 2 | or receiving any other investigational agent which womcLd be considered as a treatment for the primary neoplasm | 2 | |
| 3 | 3 | chemotherapy immunotherapy or any ancillary antitumor therapy considered | 1 | NA | NA | or receiving any other investigational agent which womcLd be considered as a treatment for the primary neoplasm . | 1 | ||
| 4 | 16 | 1 | NA | NA | note concomitant use of zoledronic acid pamidronate or denosumab is allowed and can be initiated while patients are on study therapy at investigator discretion | 1 | |||
| 5 | 4 | NA | NA | NA | patients shomcLd have recovered from any immunotherapy chemotherapy or radiation therapy related toxicities | 1 | |||
| 6 | 5 | NA | NA | NA | . | 1 | |||
| 7 | 6 | NA | NA | NA | with the exception of intravesical therapy at the time of turbt | 1 |